Biotech pharma

Rejuvenation Technologies Inc.

Website
Founded 2016Origin source ↗Checked 2026-09-15

Overview

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Reverses 10 years of telomere shortening with a single dose. Preclinical efficacy in fibrotic liver and lung disease. Entering IND-enabling. 50+ granted patents, 7 patent families. FDA INTERACT cleared.

Company description As recorded 2026-11-08

Founders & team

Previously Rejuvenation Technologies Inc., Rejuvenation Technologies

Company history As recorded 2026-11-08

John Ramunas

Founder

John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab — reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials — Phase I readout Q3 2027. Subject #1 in first human trial.

Founder profile As recorded 2026-09-15
2team members reported
Source-reported As recorded 2026-09-15

Founded 2016 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year